BEDFORD, Mass. — November 24, 2025 — Leads & Copy — Lantheus Holdings, Inc. will present new data on florbetaben F18 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, scheduled for December 1-4 in San Diego, CA.
The presentation, a poster session, will take place on Wednesday, December 3, 2025, from 7:15 AM to 5:30 PM PT. The session number is 06, titled “Clinical Trials: Imaging.” The poster, titled “Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab,” has the poster number P184. Marianne Chapleau from Life Molecular Imaging will present the poster.
Neuraceq (florbetaben F 18 injection) is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults experiencing cognitive impairment. It aids in the evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline and assists in selecting patients for amyloid beta-directed therapy, in accordance with the therapeutic products’ prescribing information.
Important Safety Information includes a risk for image interpretation and other errors, noting that errors may occur during Neuraceq image interpretation. Clinical information should not be used in interpreting images, as it may lead to inaccurate assessments. Severe brain atrophy and motion artifacts could limit the ability to distinguish between gray and white matter on scans. Image interpretation should be performed independently of the patient’s clinical information, and co-registered anatomical imaging should be used to improve localization of signal in cases of uncertainty.
Radiation risk is also a factor, as Neuraceq contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe drug handling should be ensured to protect patients and healthcare providers from unintentional radiation exposure. Patients should hydrate before and after administration and void frequently afterward.
Common adverse reactions include injection site reactions such as pain (3.4%), erythema (1.7%), and irritation (1.1%) based on data from 1,090 administrations of Neuraceq to 872 subjects.
Lantheus is a radiopharmaceutical-focused company delivering science to enable clinicians to Find, Fight and Follow disease for better patient outcomes. Headquartered in Massachusetts, Lantheus has offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, providing radiopharmaceutical solutions for nearly 70 years.
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com
Source: Lantheus Holdings, Inc.
Source: Lantheus Holdings, Inc.
